Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation

Transplant Proc. 1996 Aug;28(4):2136-7.

Authors

D S Bruce¹, K A Newell, E S Woodle, J M Millis, J B Piper, E Huss, J R Thistlethwaite

Affiliation

¹ University of Chicago, Section of Transplantation Surgery, IL 60637, USA.

PMID: 8769180

No abstract available

MeSH terms

Adult
Analysis of Variance
Antilymphocyte Serum / therapeutic use*
Azathioprine / therapeutic use
Cyclosporine / therapeutic use
Drug Therapy, Combination
Graft Rejection / epidemiology
Graft Rejection / pathology
Graft Rejection / therapy*
Graft Survival*
Humans
Immunosuppressive Agents / therapeutic use*
Muromonab-CD3 / therapeutic use*
Pancreas Transplantation / immunology
Pancreas Transplantation / mortality
Pancreas Transplantation / physiology*
Prednisone / therapeutic use
Retrospective Studies
Survival Rate
Time Factors

Substances

Antilymphocyte Serum
Immunosuppressive Agents
Muromonab-CD3
Cyclosporine
Azathioprine
Prednisone